Applied Clinical Trials-04-01-2018

How the Clinical Development Design (CDD) Framework can offer repeatable, reusable clinical designs based on "enabling information."

Debunking the six most common myths regarding electronic informed consent.

In this interview, Kevin Hudziak will expand on Lilly’s initiatives to change the face of clinical trials through patient engagement and education initiatives.

Jill Wechsler on the tug of war in accelerating orphan drug development.

Relocating the European Medicines Agency was always going to be hard-but no-one ever expected it to degenerate into farce.

The second series of results from the Center for Information and Study on Clinical Research Participation’s (CISCRP) landmark 2017 Perceptions & Insights Study.

The use of natural history (NH) studies early in clinical research can help facilitate development programs for orphan drugs.

Lisa Henderson discusses randomized clinical trials with active and non-active placebo treatments.

Click the title above to open the Applied Clinical Trials April 2018 issue in an interactive PDF format.